Abbott 2009 Annual Report : Patient Impact

Each year, Abbott products treat millions of patients around the world.

Cardiovascular disease, diabetes, autoimmune diseases and vision disorders are among the many chronic health conditions addressed by Abbott’s broad and balanced portfolio. Abbott also markets leading products in anesthesia, anti-infectives, metabolic disorders, neuroscience, pediatric and neonatal medicine, renal care, urology and reproductive health, virology, pediatric and adult nutrition, diagnostics and animal health.

With aging populations worldwide, vision care is a growing and increasingly relevant area of patient need.

Abbott is a leading provider of products and technologies for the treatment of cataracts.
Abbott is a leader in refractive products, including advanced LASIK and other laser eye procedures.
Abbott also markets Blink Tears to treat symptoms of chronic dry eye and the Complete contact lens solutions line.

Currently affecting more than 220 million people worldwide, diabetes incidence is expected to increase rapidly over the next decade.

Abbott is an established leader in glucose monitoring, with a full portfolio of innovative systems, including FreeStyle, Precision and Optium lines.
Abbott’s i-STAT and Architect systems feature various tests to diagnose diabetes and monitor glucose levels.
Abbott was the first to offer a nutritional product specifically to help patients manage their diabetes: Glucerna.
We added new approvals for our Xience Prime and Xience V drug-eluting stents to treat patients with diabetes outside the United States.

Page Top

Cardiovascular disease takes the lives of an estimated 17 million people worldwide each year and is the leading cause of death in the United States.

Abbott’s broad portfolio of leading lipid management products helps manage abnormal cholesterol levels, raising HDL (good cholesterol) and lowering LDL (bad cholesterol) and triglycerides. Products include Niaspan, Trilipix, TriCor and Simcor.
Abbott point-of-care and laboratory diagnostic instruments and tests support rapid diagnosis of, and appropriate treatment for, a heart attack.
Abbott’s Xience V and Xience Prime drug-eluting stents lead a strong portfolio of stent and related technologies that are used to open clogged arteries.

Page Top

Chronic autoimmune diseases affect millions of people worldwide. These 80 chronic illnesses occur in nearly every part of the body, from joints to skin to the gastrointestinal tract.

Abbott markets a test that aids in the diagnosis of rheumatoid arthritis on its Architect immunochemistry system.
Abbott’s Humira is a leading biologic treatment for moderate to severe rheumatoid arthritis (RA).
In addition to RA, Humira is approved for the treatment of ankylosing spondylitis, juvenile idiopathic arthritis (JIA), moderate to severe chronic plaque psoriasis, psoriatic arthritis and moderate to severe Crohn’s disease.

Consult the downloadable PDF versions of this report for printer-specific layouts.